Posted on

CaaMTech Collaboration Proves Diversity in Magic Mushroom Chemistry

CaaMTech Collaboration Proves Diversity in Magic Mushroom Chemistry

A new paper published by The Leibniz Institute for Natural Product Research in collaboration with CaaMTech reveals the complex chemistry of magic mushrooms

Scientists at The Leibniz Institute for Natural Product Research and Infection Biology working in collaboration with CaaMTech and UMASS Dartmouth recently reported new results illustrating the diverse chemistry of magic mushrooms. These results were recently published in the journal ChemBioChem in a paper titled “Genetic survey of Psilocybe natural products.”  The publication highlights numerous findings about the chemical composition of psilocybin-containing Psilocybe “magic” mushrooms including the discovery of aeruginascin in new species of mushrooms and the presence of terpene compounds.  The research highlights the chemical variability across different kinds of magic mushrooms and further underscores that different mushrooms have different properties and effects on account of that chemical variability.

Psilocybe “magic” mushrooms’ best known component, psilocybin, is a prodrug of the potent 5-HT2A agonist and powerful psychedelic compound, psilocin. However, psilocybin co-exists in these mushrooms with other less-studied, structurally similar compounds whose roles and pharmacological properties are poorly understood.  The authors of “Genetic survey of Psilocybe natural products” browsed the genomes of five species (P. azurescens, P. cubensis, P. cyanescens, P. mexicana, and P. serbica) to “​​understand more profoundly common and species-specific metabolic capacities.”  This comparison demonstrated the genetic diversity between different species of magic mushrooms, confirming a difference in their biosynthetic machinery.

The work revealed far greater metabolic diversity in Psilocybe mushrooms than previously reported. Among the findings was the metabolic production of aeruginascin (the N-trimethyl analogue of psilocybin, previously found in only three species of mushrooms including P. cubensis) in two new species of mushrooms: P. cyanescens and P. mexicana.  Additionally, the researchers found, for the first time ever in Psilocybe mushrooms, the presence of terpenes – a class of compounds responsible for some of the entourage effects in cannabis.

“Despite six decades of research on magic mushrooms, it is surprising that knowledge on the global set of Psilocybe natural products is virtually non-existent,”  said Prof. Dr. Dirk Hoffmeister, author on the paper and head of the Research Group Pharmaceutical Microbiology at The Leibniz Institute for Natural Product Research and Infection Biology in Jena, Germany. “It has been truly amazing for our team to discover that a diversity of potentially bioactive molecules is genetically encoded in the magic mushrooms.”

In light of recent efforts to legalize and decriminalize Psilocybe magic mushrooms, “Genetic survey of Psilocybe natural products” further highlights the unmet need for a more complete understanding of the mushrooms’ chemical composition and metabolome.  For example, the delayed paralytic effects known as Wood Lovers Paralysis caused by some species of Psilocybe magic mushrooms has yet to be explained.

“Five years ago magic mushrooms were treated as psilocybin sources without regard to the other compounds,” said Dr. Andrew Chadeayne, CEO of CaaMTech. “By changing the focus from mushrooms to molecules, we’re discovering the importance of many previously overlooked compounds.”

Posted on

Largest psychedelic neuroimaging study to date

UNITy: World’s first study of how DMT-induced brain changes predict improved wellbeing

University College London is raising funds for the world’s largest brain imaging study on psychedelics, aka Project UNITy.

In the first phase of the study, 150 people will receive three brain scans: one while watching a movie, one while dosed with DMT or a placebo, and another while watching a movie post-DMT trip or placebo.

Then, researchers will use an app to track participants’ changes in wellbeing for one year. 

The study will reveal which specific brain networks are altered on DMT (such as those related to vision, memory, or language), as well as which networks are linked to positive changes in wellbeing.

If successful, a second phase of the study will be conducted to see if DMT can reduce alcohol consumption and “reactivate” memory networks in hazardous drinkers.

Those who make a contribution to the study can receive goodies like trippy artwork, event tickets, and even a dinner with the scientists.

Learn more

PDF of article

Posted on

Wellbeing Digital Sciences’ Dr. Corey Hilmas Invited to Participate as a Regulatory Panelist at Probiota Americas Event

Wellbeing Digital Sciences’ Dr. Corey Hilmas Invited to Participate as a Regulatory Panelist at Probiota Americas Event

Dr. Hilmas will Represent the Company at the IPA World Congress and Probiota Americas Event Organized by William Reed Ltd. and Taking Place from June 1-3,  2022, Where he is will Comment on Key Concerns, Advances and Understandings Surrounding the Latest Developments in Prebiotics and Probiotics  

Vancouver, British Columbia, June 1, 2022 / Globe Newswire / – Wellbeing Digital Sciences Inc.  (“Wellbeing” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based mental  healthcare company focused on the development and implementation of innovative clinical solutions,  including psychedelic medicine and digital therapeutics, as supported by clinical research is pleased to  announce that Dr. Corey Hilmas MD, PhD, a member of the Company’s Medical Advisory Board, will be  participating as part of a regulatory panel (the “Panel”) at the 2022 IPA World Congress and Probiota  Americas Event (“Probiota Americas” or the “Event”).  

The Event will be held in Washington D.C. from June 1-3, 2022 and the panelists are expected to discuss  the pressing issues in the probiotics field regarding labelling, ensuring safe usage, expanding health  indications for probiotics and New Dietary Ingredient (“NDI”) notifications.1 The Panel has been  announced as consisting of four subject matter experts including Dr. Hilmas; Solange Henoud, Vice  President Regulatory and Compliance at Lallemand Health Solutions Inc.; Serna Viswanathan, JD, of the  Federal Trade Commission; and Betsy Jean Yakes, PhD, of the Food and Drug Administration.1 The Panel  will begin with short presentations and be followed by an open discussion.  

Dr. Hilmas also currently serves as the Chief Regulatory Officer of the Company’s wholly owned subsidiary,  KGK Science Inc. (“KGK”). He is a respected scientist, medical doctor, and former federal food regulator in  the United States (“US”). After having completed his medical degree and a doctorate in toxicology,  working as a principal investigator for many years, and serving on behalf of the US government at the  Food and Drug Administration (“FDA”), Dr. Hilmas combines his unique medical and scientific skillset with  extensive US regulatory training. He served as an NDI notification reviewer and as a branch chief within  the Division of Dietary Supplement Programs at the FDA. In addition to working on enforcement matters  related to supplement labelling, claims, good manufacturing practices and fraud, he also served as an 

expert witness for the FDA and Department of Justice, resulting in an FDA Award of Merit from former  FDA Commissioner Margaret Hamburg.  

IPA World Congress and Probiota Americas, a collaborative annual event that is considered the leading  occurrence for prebiotic, probiotic and the microbiota-focused food and pharmaceutical industries, is  scheduled to be held at the Crystal Gateway Marriot Hotel in Washington, DC. The Event is offered by  Nutraingredients-USA.com, also known as William Reed Ltd., a media, business intelligence and events  group dedicated to helping businesses succeed. Probiota Americas features world-leading experts who  present the latest scientific, technical, and market insights in the industry, and provides networking  opportunities for individuals and companies alike. The Event also includes the Scientific Frontiers, Probiota  Pioneers and Wellness Program sessions during the weekend.2 More information about the Event can be  found on its website: https://probiotaamericas.com/live/en/page/home.  

Management Commentary  

“We are pleased that Dr. Hilmas has been invited to speak on the Panel at the Probiota Americas event,”  said Najla Guthrie, CEO of Wellbeing. “Aside from his day-to-day role at KGK, he has enriched the  Company’s Medical Advisory Board and I believe that he will add great value to the Panel and Event as  well. We also excited for Dr. Hilmas to bring new information back to the Company after the Event. An  event like Probiota America is important to our industry as it focuses on the wellbeing of consumers,  which aligns well with our goals and beliefs,” added Ms. Guthrie.  

RSU Grant  

The Company also announces that its Board of Directors has approved a grant of 1,260,000 restricted  share units (the “RSUs”) in aggregate to an affiliate of an arm’s length consultant, pursuant to the  Company’s RSU plan. The RSUs vested immediately on the date of issuance and each RSU entitles the  holder to receive one common share of the Company in exchange.  

ABOUT KGK SCIENCE  

Founded in 1997, KGK is a leading North American contract research organization based in London,  Ontario that primarily provides high-quality clinical research trials with a focus on nutraceutical and  emerging health care products. The business has successfully helped hundreds of companies with custom designed clinical trials and claim substantiation strategies to move products into global markets. KGK’s  other existing service lines include expert regulatory support and compliance solutions, participant  recruitment, research support services and consulting services. On an approximate basis, the business to  date has produced 150 publications, executed over 400 clinical trials across more than 40 indications,  amassed 25,000 participants in its database and collected 10 million data points.  

ABOUT WELLBEING DIGITAL SCIENCES 

Wellbeing Digital Sciences Inc. is an evidence-based mental healthcare company focused on the  development and implementation of innovative clinical solutions, including psychedelic medicine and  digital therapeutics, as supported by clinical research. Its mission is supported by a network of North  American clinics that provide forward-thinking therapies and other types of treatment to patients as well  as through a contract research organization that offers clinical trials services to clients pursuing drug 

development. In essence, the Company exists to make breakthrough treatments more accessible and to  offer patients transformational experiences.  

On behalf of:  

WELLBEING DIGITAL SCIENCES INC. 

“Najla Guthrie”  

Najla Guthrie, Chief Executive Officer  

For further information, please contact:  

Nick Kuzyk, Investor Relations  

Tel: 1-844-746-6351  

Email: ir@wellbeingdigital.co  

Web: www.wellbeingdigital.co 

Twitter: @Wellbeing_IR  

Kirsten Krose, President  

SWON Public Affairs  

Tel: 613-558-9210 

Email: Kirsten@swonpublicaffairs.com 

Notice Regarding Forward-Looking Information: 

This news release contains forward-looking statements including but not limited to statements regarding  the Company’s business, assets or investments, as well other statements that are not historical facts.  Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no  assurance that the plans, intentions or expectations upon which they are based will occur. By their nature,  forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties,  both general and specific, that contribute to the possibility that the predictions, forecasts, projections and  other forward-looking statements will not occur, which may cause actual performance and results in  future periods to differ materially from any estimates or projections of future performance or results  expressed or implied by such forward-looking statements. These assumptions, risks and uncertainties  include, among other things, the state of the economy in general and capital markets in particular,  investor interest in the business and prospects of the Company.  

The forward-looking statements contained in this news release are made as of the date of this news  release. Except as required by law, the Company disclaims any intention and assumes no obligation to  update or revise any forward-looking statements, whether as a result of new information, future events  or otherwise, except as required by applicable securities law. Additionally, the Company undertakes no  obligation to comment on the expectations of, or statements made, by third parties in respect of the  matters discussed above.  

ENDNOTES 

1. “Probiota Americas panel to delve into NDI guidance, labeling, additional issues”, by Hank Schultz,  NURTAingredients-USA.com, May 19, 2022, https://www.nutraingredients usa.com/Article/2022/05/19/probiota-americas-panel-to-delve-into-ndi-guidance-labeling additional-issues 

2. “Probiota Americas 2022”, Probiota Americas, 2022,  https://probiotaamericas.com/live/en/page/home 

SOURCE: WELLBEING DIGITAL SCIENCES INC.

‍

Posted on

Lexston Announces Non-Brokered Unit Private Placement

Lexston Announces Non-Brokered Unit Private Placement

Vancouver, British Columbia, June 1, 2022. Lexston Life Sciences Corp. (the “Company”) (CSE: LEXT) (OTCQB: LEXTF) announces a non-brokered private placement consisting of up to 15,000,000 units (the “Units”) at a purchase price of $0.05 per Unit to raise gross proceeds of up to $750,000 (the “Private Placement”). Each unit will consist of one common share in the capital of the Company and one share purchase warrant (a “Warrant”). Each full warrant will entitle the holder to purchase one additional
common share in the capital of the Company for a period of five years, at a purchase price of $0.075 per Share.

The Company may pay a finder’s fee in connection with the Private Placement within the maximum amount permitted by the policies of the Canadian Securities Exchange (the “Exchange”) and the applicable securities laws. Certain directors, officers and insiders of the Company may participate in the Private Placement. The Private Placement is subject to several conditions, including receipt of all necessary corporate and regulatory approvals, including the Exchange. All securities to be issued in connection with the Private Placement will be subject to a statutory hold period of four months plus a day from the date
of issuance in accordance with applicable securities legislation.

The net proceeds from the Private Placement will be used by the Company for general working capital.

On Behalf of the Board of Directors
LEXSTON LIFE SCIENCES CORP.
Jagdip Bal Chief Executive Officer
Telephone: (604) 928-8913

The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

Posted on

Mindmed Announces Voting Results for Annual General and Special Meeting

Mindmed Announces Voting Results for Annual General and Special Meeting

NEW YORK, June 1, 2022 — Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), announces the voting results of the Company’s annual general and special meeting of shareholders held on June 1, 2022 (the “Meeting”). 

Election of Directors

The five nominees of management were elected as directors at the Meeting. The voting results for the election of each director nominee are as follows:

Name of NomineeNumber of Votes ForPercentage of Votes ForNumber of Votes WithheldPercentage of Votes Withheld
Carol A. Vallone66,244,518.6889.04%8,146,247.4710.95%
Andreas Krebs 71,955,691.9796.72%2,435,074.183.27%
Brigid A. Makes65,578,489.1688.15%8,812,276.9911.84%
Robert Barrow70,713,915.0595.05%3,676,851.104.94%
Dr. Miri Halperin Wernli70,671,060.8794.99%3,719,705.285.00%

Appointment of Auditor

At the Meeting, KPMG LLP was appointed as the auditor of the Company for the ensuing year and the directors were authorized to fix the remuneration to be paid to the auditor.

Alteration to the Company’s Share Structure

At the Meeting, shareholders approved the alteration to the Company’s share structure to eliminate the Multiple Voting Shares of the Company and re-designate the Subordinate Voting Shares as Common Shares of the Company. 

About MindMed

MindMed is a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, with a particular focus on psychiatry, addiction, pain and neurology. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative drug candidates, with and without acute perceptual effects, targeting the serotonin, dopamine and acetylcholine systems.

MindMed trades on NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED.

For Media: media@mindmed.co

For Investors: ir@mindmed.co

Posted on

Greenbrook TMS to Host Investor Webcast on June 7, 2022

Greenbrook TMS to Host Investor Webcast on June 7, 2022

June 1, 2022 – Toronto, ON – Greenbrook TMS Inc. (TSX: GTMS) (“Greenbrook” or the “Company”) is pleased to announce that it will host a webcast investor presentation on Tuesday, June 7th, 2022, at 2:00 PM ET.

During the webcast, Bill Leonard, Chief Executive Officer, will conduct a presentation that will cover key areas of Greenbrook’s business. After the formal presentation, investors will have an opportunity to ask relevant questions through an interactive Q&A portal.

To listen to the webcast or to ask questions during the live event, please pre-register at the following link: https://event.webcasts.com/starthere.jsp?ei=1545464&tp_key=65f37425dc.

An archived version of the webcast and presentation will be available on the Company’s website, https://www.greenbrooktms.com/investors/events.htm following the event.

About Greenbrook TMS Inc.

Operating through 148 Company-operated treatment centers, Greenbrook is a leading provider of Transcranial Magnetic Stimulation (“TMS”) therapy, an FDA-cleared, non-invasive therapy for the treatment of Major Depressive Disorder and other mental health disorders, in the United States. TMS therapy provides local electromagnetic stimulation to specific brain regions known to be directly associated with mood regulation. Greenbrook has provided more than 840,000 TMS treatments to over 24,000 patients
struggling with depression.

For further information please contact:

Glen Akselrod
Investor Relations
Greenbrook TMS Inc.
Contact Information:
investorrelations@greenbrooktms.com
1-855-797-4867

Posted on

Cannabis Global Comments on Its Dramatic Business Turnaround – While Many Cannabis Companies Are Retrenching, CBGL Exceeds in Most Categories

Cannabis Global Comments on Its Dramatic Business Turnaround – While Many Cannabis Companies Are Retrenching, CBGL Exceeds in Most Categories

LOS ANGELES, CA / ACCESSWIRE / June 1, 2022 / Cannabis Global, Inc. (OTC PINK:CBGL), a licensed Los Angeles-based manufacturer and distributor in the cannabis sector, today prepares to close out its third fiscal quarter ending May 31, 2022, with significant growth across all categories. The Company expects to report a considerable increase in the number of product SKUs shipping during the quarter, a substantial expansion of its retail presence, and most importantly, strong revenue growth when much of the California cannabis industry is retrenching. Cannabis Global expects the strong growth it is experiencing to continue into subsequent quarters.

“We are significantly exceeding our internal goals. We believe we are set on a solid growth trajectory as we add numerous product lines in high growth areas and increase our marketing presence. We could not be more excited about our turnaround. We see a strong path for us through the rest of 2022,” commented Company CEO Arman Tabatabaei.

While maintaining its current book of business, which is already experiencing strong growth, Cannabis Global will be seeking to further boost its growth prospects by launching over the next few weeks: 1) a high-end Northern Lights brand with nine new products of premium flower and solventless edibles, 2) a new “El Cheapo” edibles line based on the product positioning of significantly better ingredients at industry beating prices, 3) solventless rosin vape cartridges, 4) three new SKUs of premium rosin enhanced pre-rolls, 5) three new varieties of packaged cannabis flower, and 6) a new distribution agreement for an additional major Southern California delivery service.

In addition, the Company is pleased to announce work has already begun on manufacturing and distributing a new line of indoor cultivated exotic flower strains, with the first being the highly conveyed super exotic RS11 strain, which is now ready for distribution. The Company plans to introduce flower and solventless products based on RS11 over the coming two weeks.

Mr. Tabatabaei continued, “We are in a great position as we continue to experience a meaningful turnaround in our business. Our teams are motivated and performing ahead of expectations, and we have selected some unique product directions, which are now about to launch. We plan to further accelerate growth in our business by expanding our selective vertical integration strategy, being highly selective relative to the types of products we introduce, and by continuing to make wise choices relative to marketing partnerships. Finally, we appreciate all the support our new customers, investors, and our board of directors have provided to us as we revamped our operations to further expand into the California cannabis marketplace.”

About Cannabis Global, Inc.

Cannabis Global, Inc. is a Los Angeles-based, fully audited and reporting Company with the U.S. Securities & Exchange Commission, trading under the stock symbol CBGL. We are an emerging force in the cannabis marketplace with a growing product and proprietary intellectual property portfolio. We are marketing and producing Comply Bag™, an innovative solution for cannabis storage, transport and tracking. Our subsidiary, Natural Plant Extract (NPE), is a Southern California licensed cannabis manufacturer and distributor which licenses our technologies to produce edibles for the cannabis marketplace. Cannabis Global has filed three non-provisional and multiple provisional patents for cannabis infusion and nanoparticle technologies and continues an active research & development program.

Forward-Looking Statements

This news release contains “forward-looking statements” which are not purely historical and may include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities and words such as “anticipate”, “seek”, intend”, “believe”, “estimate”, “expect”, “project”, “plan”, or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects, the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based products. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission. For more information, please visit www.sec.gov.

Corporate contact:

Arman Tabatabaei
IR@cannabisglobalinc.com
+1-(310)-986-4929

IR Contact:

Stuart Smith
https://www.smallcapvoice.com/
ssmith@smallcapvoice.com

SOURCE: Cannabis Global, Inc.

View source version on accesswire.com:
https://www.accesswire.com/703396/Cannabis-Global-Comments-on-Its-Dramatic-Business-Turnaround-While-Many-Cannabis-Companies-Are-Retrenching-CBGL-Exceeds-in-Most-Categories

Posted on

Ketamine Wellness Centers (KWC) Launches SPRAVATO® Nasal Spray Therapy in Minneapolis, Salt Lake City and Dallas

Ketamine Wellness Centers (KWC) Launches SPRAVATO® Nasal Spray Therapy in Minneapolis, Salt Lake City and Dallas

Largest Ketamine Provider in the U.S. Now Offering FDA-Approved Esketamine Nasal Spray Offering for Adults in Six Cities

GILBERT, AZ, June 1, 2022 – Ketamine Wellness Centers (KWC), the largest ketamine therapy provider in the U.S. and a subsidiary of Delic Holdings Corp (“Delic” or the “Company”) (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), has expanded the availability of SPRAVATO® to three new cities and increased the total number of clinics offering the FDA-approved esketamine nasal spray to six. Starting June 1, the KWC clinics in Minneapolis, Salt Lake City and Dallas will join the Houston, Las Vegas and Seattle locations in offering SPRAVATO to their patient base.

Taken with an oral supplement, SPRAVATO is an FDA-approved treatment for adults experiencing treatment-resistant depression (TRD) or depressive symptoms associated with major depressive disorder (MDD). Patients interested in pursuing this treatment option will work with the company’s experienced intake and screening teams to ensure that SPRAVATO is the most positive choice for them. KWC providers are trained to administer SPRAVATO treatments in the right care and patient safety settings.

Many of the nation’s largest insurers have included SPRAVATO in their coverage. Insurance experts at KWC are available to help patients navigate the complexities of healthcare coverage and assist in determining coverage and potential out-of-pocket costs.

“KWC aims to provide a diverse range of accessible and clinically-supported mental healthcare options to our national patient community,” said Kevin Nicholson, CEO of KWC and Chief Operating Officer of Delic. “We’re excited to continue growing the availability of SPRAVATO, the first treatment of its kind, and we look forward to helping more patients across our network of clinics understand how it can benefit their mental health as we expand into new states.” 

For more information about Ketamine Wellness Centers’ locations, services and hours of operation, please visit https://www.ketaminewellnesscenters.com/locations/.

About Ketamine Wellness Centers

Ketamine Wellness Centers (KWC) is the largest ketamine therapy provider in the United States with 13 clinic locations serving communities across nine states. Since 2011 KWC has been a trusted leader in bringing IV ketamine therapy into mainstream health care. KWC has provided over 60,000 treatments to clinically eligible patients, from young adults to seniors, in addition to developing specialized programs for veterans and first responders. The KWC team, including a core group of physicians, psychologists, clinicians, and executives, is dedicated to providing value-based, personalized, clinically controlled ketamine infusion care for people suffering from treatment-resistant depression, anxiety, PTSD, OCD and chronic pain. KWC’s scalable business and treatment model is designed for further rapid expansion along with breakthrough innovations in effective therapies and services.

About Delic Corp, Inc.

Delic is a leader in new medicines and treatments for a modern world, improving access to health benefits across the country and reframing the conversation on psychedelics. The Company owns and operates an umbrella of related businesses, including the largest chain of psychedelic wellness clinics in the country, including Ketamine Infusion Centers and Ketamine Wellness Centers; the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology, Delic Labs; the premier psychedelic wellness event, Meet Delic; and trusted media and e-commerce platforms Reality Sandwich and Delic Radio. Delic is backed by a team of industry and cannabis veterans and a diverse network, whose mission is to provide education, research, high-quality products, and effective treatment options to the masses.

About SPRAVATO®

SPRAVATO® (esketamine) CIII nasal spray is a nonselective, noncompetitive antagonist of the N-methyl-D-aspartate (NMDA) receptor – an ionotropic glutamate receptor. It is a first-of-its kind medicine approved by the FDA in two major depressive disorder (MDD) subpopulations with high unmet need.1

SPRAVATO® is approved in the United States, in conjunction with an oral antidepressant, to treat adults with treatment-resistant depression (TRD) and to treat depressive symptoms in adults with MDD with acute suicidal ideation or behavior.

Reference

1. Duman RS. F1000Research. 2018;7:F1000.

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and does not accept responsibility for the adequacy or accuracy of this release.

This news release does not constitute an offer to sell, or a solicitation of an offer to buy, any securities ‎in the United States. The securities have not been and will not be registered ‎under the United States ‎Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state ‎securities laws and may not be offered or ‎sold within the United Statesunless registered under the U.S. ‎Securities Act and applicable state securities laws or an ‎exemption from such registration is available.‎

Forward-Looking Information and Statements

This press release contains certain “forward-looking information” within the meaning of applicable ‎Canadian securities ‎legislation and may also contain statements that may constitute “forward-looking ‎statements” within the meaning of ‎the safe harbor provisions of the United States Private Securities ‎Litigation Reform Act of 1995. Such forward-looking ‎information and forward-looking statements are not ‎representative of historical facts or information or current ‎condition, but instead represent only the ‎Company’s beliefs regarding future events, plans or objectives, many of ‎which, by their nature, are ‎inherently uncertain and outside of Delic’s control. Generally, such forward-looking ‎information or ‎forward-looking statements can be identified by the use of forward-looking terminology such as ‎‎”plans”, ‎‎”expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, ‎‎‎”anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or may ‎contain ‎statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be ‎taken”, “will continue”, ‎‎”will occur” or “will be achieved”. The forward-looking information and forward-‎looking statements contained herein ‎may include, but are not limited to: information regarding the timing or terms upon which the Transaction will be completed; potential benefits of the Transaction;  anticipated continued growth in the health and wellness sector (and, in particular, related to psychedelics); the ability of Delic to successfully achieve business ‎objectives, ‎and expectations ‎for other economic, ‎business, and/or competitive factors.‎

By identifying such information and statements in this manner, Delic is alerting the reader that ‎such ‎information and statements are subject to known and unknown risks, uncertainties and other factors ‎that may cause ‎the actual results, level of activity, performance or achievements of Delic to be ‎materially different from those ‎expressed or implied by such information and statements. Such risks and other factors may include, but are not limited to: risks and uncertainties relating to the Transaction not closing as planned or at all or on terms and conditions set forth in the Merger Agreement; incorrect assessment of the value and potential benefits of the Transaction; direct and indirect material adverse effects from the COVID-19 pandemic; inability to obtain future financing on suitable terms; failure to obtain required regulatory and other approvals; risks inherent in the psychedelic treatment sector; changes in applicable laws and regulations; and failure to comply with applicable laws and regulations.

In addition, in connection with the forward-looking ‎information and forward-looking statements contained in this press ‎release, Delic has made certain ‎assumptions. These assumptions include, but are not limited to: assumptions as to the time required to negotiate a definite agreement and complete matters related to the Transaction; the ability to consummate the Transaction; ‎the ability of the parties to ‎obtain, in a timely manner, the requisite regulatory, corporate and other third party approvals and the satisfaction of ‎other conditions to the ‎consummation of the Transaction on the proposed terms; the potential impact of the announcement or consummation of the Transaction on ‎relationships, ‎including with regulatory bodies, employees, suppliers, customers and competitors; ‎changes in general economic, ‎business and political conditions, including changes in the financial ‎markets; changes in applicable laws; compliance ‎with extensive government regulation; and the diversion ‎of management time on the Transaction.‎

Should one or more of these risks, uncertainties or other factors materialize, or should assumptions ‎underlying the ‎forward-looking information or statements prove incorrect, actual results may vary ‎materially from those described ‎herein as intended, planned, anticipated, believed, estimated or ‎expected.‎

Although Delic believes that the assumptions and factors used in preparing, and the expectations ‎contained ‎in, the forward-looking information and statements are reasonable, undue reliance should not ‎be placed on such ‎information and statements, and no assurance or guarantee can be given that such ‎forward-looking information and ‎statements will prove to be accurate, as actual results and future events ‎could differ materially from those anticipated ‎in such information and statements. The forward-looking ‎information and forward-looking statements contained in this ‎press release are made as of the date of ‎this press release, and Delic does not undertake to update any ‎forward-looking information ‎and/or forward-looking statements that are contained or referenced herein, except in ‎accordance with ‎applicable securities laws. All subsequent written and oral forward- looking information and ‎statements ‎attributable to Delic or persons acting on its behalf is expressly qualified in its entirety by this ‎‎notice.‎

Investor Relations Contact
Rich Rodriguez
rich@deliccorp.com

Media Relations Contact
Clare Redlick
MATTIO Communications clare@mattio.com

Posted on

Doseology Opens to American Investors

Doseology Opens to American Investors

Vernon, British Columbia, June 1, 2022 – Doseology Sciences Inc. (CSE: MOOD) (FSE: VU7) (OTC: DOSEF) (“Doseology” or the “Company”), a life sciences company focused on mental health and wellness, is pleased to announce that its common shares (the “Shares”) were approved for trading on the OTC Pink Open Market in the United States under the symbol “DOSEF”. The Shares will continue to trade on the Canadian Securities Exchange under the symbol “MOOD” and on the Frankfurt Stock Exchange under the symbol “VU7”. The Company has also applied to uplist its Shares from the Pink Open Market to the OTCQB Market in the United States.

The Company is pleased to announce that the Shares have been approved for eligibility for book-entry and depository services through the Depository Trust Company (“DTC”) in the United States, which will facilitate electronic clearing and settlement of transfers of the Shares.

DTC is a subsidiary of the Depository Trust & Clearing Corporation, a U.S. company that manages the electronic clearing and settlement of publicly traded companies. Securities that are eligible to be electronically cleared and settled through DTC are considered “DTC eligible”. With an accelerated settlement period and reduced costs for investors and brokers, DTC eligibility is expected to simplify the process of trading and enhance liquidity of the Company’s shares in the United States.

Ralph Olson, CEO of the Company, stated:  “We are pleased to have obtained our dual USA listing and DTC eligibility. This eligibility will simplify the process of trading shares in the USA, which will be beneficial to Doseology and our shareholders. With DTC eligibility, the increased accessibility and visibility is expected to attract greater investment and trading liquidity from American investors as our shares will be available to a broader range of investors as we continue to expand our business.”

On Behalf of the Board of Directors

Ralph Olson
Chief Executive Officer
Doseology Sciences Inc

About OTC Pink Open Market

The Pink Open Market, operated by OTC Markets Group Inc., provides brokers with a regulated platform for transparent trading and best execution. Brokers quote a wide spectrum of companies on this market, including foreign companies that limit their disclosure in the U.S., penny stocks and shells. To be eligible for quotation on the Pink Market, companies must comply with the requirements of Securities Exchange Act Rule 15c2-11, including providing current information to the investing public.

About Doseology Sciences (CSE: MOOD) (FSE: VU7) (OTC: DOSEF)

Doseology Sciences Inc. is building a progressive brand focused on mental health and wellness through cultivation, extraction and innovative nutraceutical and pharmaceutical products. Doseology aims to make a meaningful impact on the mental health pandemic by utilizing and developing psychedelic and non-psychedelic compounds within the functional fungi and plant-derived drug markets. With a vertically integrated approach, Doseology intends to process and distribute products at its facilities in Vernon, British Columbia, in accordance with applicable laws to ensure safe and high-quality production. Doseology’s medicinal mushroom products, including tinctures, powders and supplements, are available on doseology.com. 

For further information contact:

Investor Relations: investor@doseology.com
General Inquiries: hello@doseology.com 
Telephone: 236-349-0064
Website: doseology.com

Forward-Looking Statements

This press release contains statements that constitute “forward‐looking information” within the meaning of applicable securities laws. Forward‐looking information is often identified by the words “may,” “would,” “could,” “should,” “will,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “expect” or similar expressions. Readers are cautioned that forward‐looking information is not based on historical facts but instead reflects the Company’s management’s expectations, estimates or projections concerning the business of the Company’s future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although the Company believes that the expectations reflected in such forward‐looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance, or achievements. Among the key factors that could cause actual results to differ materially from those projected in the forward‐looking information are the following: changes in general economic, business and political conditions, including changes in the financial markets; decreases in the prevailing prices for products in the markets that the Company operates in; adverse changes in applicable laws or adverse changes in the application or enforcement of current laws; regulations and enforcement priorities of governmental authorities; compliance with government regulation and related costs; and other risks described in the Company’s prospectus. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward‐looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated, or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward‐looking information except as otherwise required by applicable law. For more information, investors should review the Company’s filings which are available on SEDAR.

No securities regulatory authority has either approved or disapproved of the contents of this press release. The Company’s securities have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, or any state securities laws, and may not be offered or sold in the United States, or to or for the account or benefit of any person in the United States, absent registration, or an applicable exemption from the registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities in the United States, or in any other jurisdiction in which such offer, solicitation or sale would be unlawful.

The CSE does not accept responsibility for the adequacy or accuracy of this release.

Posted on

Ehave, Inc. Announces Psychedelics Precision Medicine Platform For Clinical Research

Ehave, Inc. Announces Psychedelics Precision Medicine Platform For Clinical Research

  • AI-driven discovery platform enables new way to find novel pathways, as well as progress towards identifying patients who may better respond to drugs in the clinic
  • Genetic test kit evaluates an individual’s overall sensitivity and risk profile associated with psychedelic-assisted therapy

MIAMI, June 01, 2022 (GLOBE NEWSWIRE) — Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a leading healthcare services and technology company, announced today its KetaDASH subsidiary will begin using precision medicine to improve patient outcomes through its partnership with Entheon Biomedical Corp.’s (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (“Entheon”) wholly-owned subsidiary, HaluGen Life Sciences Inc. (“HaluGen”) to use its psychedelics genetic test kit. KetaDASH will become one of the first psychedelic companies to use precision medicine to test patients by using HaluGen’s expanded psychedelics genetic testing panel, which analyzes a series of relevant DNA biomarkers and utilizes pre-screening mental health surveys in order to provide insights into an individual’s risk and potential of adverse reactions with the use of ketamine.

By utilizing precision medicine, medical professionals will be able to test patients for genetic, personal and familial insights to better inform each patient’s psychedelic assisted therapy experience. KetaDASH believes that DNA test results, and data from mental-health surveys, will allow individuals to make more informed decisions around psychedelic assisted therapy, potential side effects and risk profile.

Genetics can play a key role in determining how an individual may respond to psychedelic-assisted psychotherapy. The gene mutation CYP2B6 can influence the metabolism of ketamine for the 10-20% of people that carry a specific CYP2B6 gene variant. Similarly, the HTR2A gene mutation, which is carried by approximately 20% of the population, can impact how a person responds to serotonin, which is the primary mechanism of action for serotonergic psychedelics such as psilocybin, LSD and DMT. Precision medicine will provide KetaDASH with the ability to tailor the treatment based on an individual or sub-groups variability in genes and lifestyle choice.

Ben Kaplan, CEO of Ehave, said, “The benefit of the psychedelic profile is that it will enable the individuals and healthcare professionals at KetaDASH to personalize psychedelic therapy by providing an individual’s metabolic status for ketamine with their CYP2B6 genotype. We are pleased with the results from the initial launch of KetaDASH in the San Francisco and Sacramento area. Having the ability to personalize psychedelic therapy will prove beneficial and set us apart from our competitors as we expand KetaDASH into other markets.”

Timothy Ko, CEO of Entheon, commented, “We are thrilled to support Ehave and KetaDASH with the use of our genetic test kits. We believe that personalization will become an increasingly important feature of the psychedelic therapeutics landscape and applaud the pioneering steps that they are taking to deliver a standard of care that takes into account the individual nuance of every patient.”

About Ehave, Inc.

Ehave is a leading healthcare services and technology company, focused on progressing psychedelics-to-Therapeutics by engineering novel compounds and new treatment protocols for treating brain health. Together with our network of scientists and mental health professionals, we are on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues, leveraging clinical data to help us achieve optimal patient outcomes. Ehave’s operations span across the entire USA, Canada, Jamaica, and Australia. Additional information on Ehave can be found on the Company’s website at: www.ehave.com.

About Entheon Biomedical Corp.

Entheon is a biotechnology research and development company committed to developing and commercializing a portfolio of safe and effective Dimethyltryptamine based psychedelic therapeutic products (“DMT Products”) for the purposes of treating addiction and substance use disorders. Subject to obtaining all requisite regulatory approvals and permits, Entheon intends to generate revenue through the sale of its DMT Products to physicians, clinics and licensed psychiatrists in the United States, certain countries in the European Union and throughout Canada. https://www.entheonbiomedical.com

About HaluGen Life Sciences Inc.

HaluGen has developed a DNA testing and personalized psychedelic pre-screening platform that provides genetic, personal and familial insights to better inform the psychedelic experience, with the goal of improving patient care and reducing side effects and risk. HaluGen’s genetic-based psychedelic pre-screening platform helps evaluate an individual’s overall sensitivity and risk profile when using hallucinogenic drugs. This platform is the first of its kind with test results within days. https://www.halugen.com

Forward-Looking Statement Disclaimer

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements: (i) the initiation, timing, progress and results of the Company’s research, manufacturing and other development efforts; (ii) the Company’s ability to advance its products to successfully complete development and commercialization; (iii) the manufacturing, development, commercialization, and market acceptance of the Company’s products; (iv) the lack of sufficient funding to finance the product development and business operations; (v) competitive companies and technologies within the Company’s industry and introduction of competing products; (vi) the Company’s ability to establish and maintain corporate collaborations; (vii) loss of key management personnel; (viii) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its products and its ability to operate its business without infringing the intellectual property rights of others; (ix) potential failure to comply with applicable health information privacy and security laws and other state and federal privacy and security laws; and (x) the difficulty of predicting actions of the USA FDA and its regulations. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement unless required by law. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is contained under the heading “Risk Factors” in Ehave, Inc.’s Registration Statement on Form F-1 filed with the Securities and Exchange Commission (SEC) on September 24, 2015, as amended, which is available on the SEC’s website, http://www.sec.gov.

For Media and Investor Relations, please contact:

David L. Kugelman

(866) 692-6847 Toll Free – U.S. & Canada

(404) 281-8556 Mobile and WhatsApp

Email: Ir@Ehave.com

Skype: kugsusa

LinkedIn: https://www.linkedin.com/in/davidkugelman